Worthington Steel
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 4.6K
- Market Cap
- -
- Introduction
Worthington Steel, Inc. engages in the steel processing business in connection with the separation and the distribution. Its products include cold rolled steel, hot rolled, galvanized, first operation blanking, dry film lubricant, cut-to-length sheets, pickling, annealing, one pass rolling, temper rolling, slitting, and oscillate slitting. The company was founded in 1955 and is headquartered in Columbus, OH.
Weight Gain Combined with Delayed Motherhood Nearly Triples Breast Cancer Risk, Study Finds
• New research reveals women who gain significant weight after age 20 and delay childbirth until after 30 (or remain childless) face a 2.7 times higher risk of developing breast cancer.
• The study, presented at the European Congress on Obesity, is the first to establish how weight gain and age of first birth interact to affect breast cancer risk in women.
• Researchers analyzed data from nearly 48,500 women with an average age of 57, identifying over 1,700 breast cancer cases during the six-year follow-up period.
Akero's Efruxifermin Shows Promise in Reversing Cirrhosis Due to MASH in Phase 2b Trial
• Akero Therapeutics' Efruxifermin (EFX) demonstrated statistically significant cirrhosis reversal in patients with MASH in a Phase 2b trial.
• In patients with baseline and week 96 biopsies, 39% treated with 50mg EFX showed cirrhosis reversal without worsening MASH, compared to 15% with placebo.
• The SYMMETRY study underscores the benefit of longer EFX treatment, showing a doubling of effect size from weeks 36 to 96 in the 50mg group.
• Akero is continuing to evaluate 50mg EFX in the Phase 3 SYNCHRONY Outcomes study for patients with compensated cirrhosis due to MASH.
© Copyright 2025. All Rights Reserved by MedPath